• Alex B Garton, John Dudzinski, and Peter R Kowey.
• Division of Cardiovascular Disease, Lankenau Medical Center, Wynnewood, Pennsylvania, USA.
• J. Cardiovasc. Electrophysiol. 2014 Dec 1; 25 (12): 1411-8.

AbstractAtrial fibrillation is the most common arrhythmia and ablation is becoming more prevalent as a treatment option. Appropriate treatment of atrial fibrillation mandates thromboembolic prophylaxis, and atrial fibrillation ablation periprocedural management of oral anticoagulation is paramount because of the unique susceptibility for thromboembolism that exists for a patient undergoing ablation. Uninterrupted warfarin therapy is the current standard approach for periprocedural atrial fibrillation anticoagulation. Novel oral anticoagulants, including direct thrombin and factor Xa inhibitors, are being used more frequently for thromboembolic prophylaxis in atrial fibrillation patients, but the best strategy for using novel oral anticoagulants in periprocedural anticoagulation is unknown. Optimal periprocedural anticoagulation management strategies with oral anticoagulants, limitations of using novel oral anticoagulants, and future directions in this field are discussed.© 2014 Wiley Periodicals, Inc.

21 keywords...

hide…